Investing.com - 23Andme Holding Co reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. 23Andme Holding Co...
By Davit Kirakosyan Each day Wall Street research analysts initiate new coverage on stocks in the sectors they follow and establish ratings, like Buy/Hold/Sell, set price targets,...
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company's segments include Consumer & Research Services and Therapeutics. The Consumer & Research Services segment comprises its Personal Genome Service (PGS), telehealth business, and research services. Its PGS service provides customers with a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. Its telehealth platform provides patients with access to medical consultation and treatment. Through its research services, it uses its database of genetic and phenotypic information to identify targets for drug development. The Therapeutics segment focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies to improve patients lives.
|Average||5.69 (+135.02% Upside)|
|No. of Analysts||4|